Hosted on MSN

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

NEW YORK, November 3, 2025 – Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet ...
Benzinga.com

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024

From expanding partnerships to advancing trials, Mainz Biomed NV (NASDAQ:MYNZ), the molecular genetics diagnostic company, had a busy 2024 – which appears to have shown in its revenue growth. The ...
Business Insider

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
Seeking Alpha

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025 NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical ...
Seeking Alpha

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

Orchestra BioMed holds two best-in-class medical device therapies targeting large markets, with strong partnerships and equity investments from Medtronic and Terumo. Both AVIM Therapy and Virtue SAB ...
Hosted on MSN

TD Cowen initiates Orchestra BioMed (OBIO), cites high-margin potential in lead cardiovascular programs

Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) is one of the best biotech penny stocks to buy according to analysts. On December 10, TD Cowen analyst Joshua Jennings initiated coverage of Orchestra ...